Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA approves William Demant hearing aid against tinnitus-Reuters


Thursday, 27 Mar 2014 09:55am EDT 

William Demant Holding A/S:Receives approval for its first hearing aid reducing tinnitus from the United States Food and Drug Administration (FDA)-Reuters.The new hearing aid is especially targeted at the US Veterans Administration (VA), a government-led program for US military veterans, which makes up about 20 percent of all hearing aid units dispensed in the US. 

Company Quote

560.0
3.0 +0.54%
9:48am EST